Astellas To Pay $7M To End Mycamine FCA Suit

Law360, Washington (April 16, 2014, 4:30 PM ET) -- Astellas Pharma US Inc. has agreed to pay $7.3 million to settle a whistleblower False Claims Act suit from a former sales representative alleging that it marketed antifungal treatment Mycamine off-label for pediatric use and that as a result, Medicaid paid for unlawful prescriptions of the drug, the U.S. Department of Justice announced Wednesday.

The deal resolves allegations that between 2005 and 2010, Astellas — the U.S. unit of a Japanese drugmaker — knowingly promoted Mycamine for pediatric use, without approval from the U.S. Food and...
To view the full article, register now.